US FDA Approves Rett Syndrome Drug by Acadia
The US FDA granted Acadia Pharmaceuticals’ DAYBUE (trofinetide) approval for the treatment of Rett syndrome in adults and children over the age of two last Friday. DAYBUE is the first and only medication approved for the treatment of Rett syndrome. Acadia and the Rett community have reached a significant turning point today. Steve Davis, CEO […]
Continue Reading